Figure 5. NKTR-255 increases the... | American Society of Hematology

Figure 5.

NKTR-255 increases the antitumor efficacy of human CD19 CAR T cells in vivo in a dose-dependent manner. NSG mice were injected IV with 5 × 105 Raji cells. Seven days later, tumor-bearing mice received 0.8 × 106 CD19 CAR T cells (1:1, CD8+:CD4+) IV. Cohorts of mice (n = 3-4 per group) received either PBS, NKTR-255 at 0.03 mg/kg, or NKTR-255 at 0.3 mg/kg IV starting on day 6 after CAR T-cell infusion followed by weekly doses from day 14. One control group received PBS without CAR T cells. (A) Schematic of the experimental setup. (B) Bioluminescence imaging of the Raji tumor burden at the indicated time points. (C) Average tumor radiance. (D) Kaplan-Meier survival curve. Max, maximum; Min, minimum.

NKTR-255 increases the antitumor efficacy of human CD19 CAR T cells in vivo in a dose-dependent manner. NSG mice were injected IV with 5 × 10⁵ Raji cells. Seven days later, tumor-bearing mice received 0.8 × 10⁶ CD19 CAR T cells (1:1, CD8⁺:CD4⁺) IV. Cohorts of mice (n = 3-4 per group) received either PBS, NKTR-255 at 0.03 mg/kg, or NKTR-255 at 0.3 mg/kg IV starting on day 6 after CAR T-cell infusion followed by weekly doses from day 14. One control group received PBS without CAR T cells. (A) Schematic of the experimental setup. (B) Bioluminescence imaging of the Raji tumor burden at the indicated time points. (C) Average tumor radiance. (D) Kaplan-Meier survival curve. Max, maximum; Min, minimum.

This Feature Is Available To Subscribers Only